Loading…
Comparison of purified protein derivative and vitamin D in the treatment of recalcitrant warts
Background: Viral warts are caused by human papillomavirus. There are various treatment modalities which cause destruction of the warts. Not all of them are very effective on difficult-to-treat warts. For the treatment of difficult-to-treat warts, new and effective treatment includes intralesional i...
Saved in:
Published in: | Clinical dermatology review 2021-01, Vol.5 (1), p.54-58 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c2850-4908f8c1e6eebc99b04563fc56b8803213aaf457f6682706c97c039cc8fe63803 |
---|---|
cites | |
container_end_page | 58 |
container_issue | 1 |
container_start_page | 54 |
container_title | Clinical dermatology review |
container_volume | 5 |
creator | Leena Raveendra Belliappa Pemmanda Raju Kumar K C Dharam Vinutha Mohan Kumar Yadav |
description | Background: Viral warts are caused by human papillomavirus. There are various treatment modalities which cause destruction of the warts. Not all of them are very effective on difficult-to-treat warts. For the treatment of difficult-to-treat warts, new and effective treatment includes intralesional immunotherapy. Objectives: The aim was to evaluate and compare the efficacy of intralesional Vitamin D and tuberculin purified protein derivative (PPD) as immunotherapy in difficult-to-treat warts. Materials and Methods: A total of 100 patients with difficult-to-treat viral warts were enrolled in this randomized controlled study. Group A patients were injected intralesionally with 2.5 TU of tuberculin PPD (0.1 ml) and Group B patients were injected with 0.1 ml of Vitamin D3 per lesion to a maximum of ten lesions. The clinical assessment was done by photographic measurements at baseline, before each treatment session, and after the completion of the treatment every 2 weeks for a total of four sessions. Unpaired t-test was used to compare both the treatment modalities. Results: In Group A, a total of 38 (76%) patients showed complete clearance and 12 (24%) showed partial response, while in Group B, a total of 42 (84%) patients showed complete clearance, while 8 (16%) showed partial response. There was no statistically significant difference between both the modalities. Conclusions: Intralesional Vitamin D3 injection and intralesional PPD may be a treatment option for difficult-to-treat warts that are unresponsive to conventional treatments. Both are equally effective with minimal side effects. |
doi_str_mv | 10.4103/CDR.CDR_51_20 |
format | article |
fullrecord | <record><control><sourceid>doaj</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a3f073a2704a4fbe91edc7ef1f1840d1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a3f073a2704a4fbe91edc7ef1f1840d1</doaj_id><sourcerecordid>oai_doaj_org_article_a3f073a2704a4fbe91edc7ef1f1840d1</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2850-4908f8c1e6eebc99b04563fc56b8803213aaf457f6682706c97c039cc8fe63803</originalsourceid><addsrcrecordid>eNo9TslKBDEQDaLgMM7Re36gx-ydHKXHZUAQRMGTTXW6ohmmF9JxxL-3XfBQ9RZePYqQc87WijN5UW0e1vPUmteCHZGF0EoUWgt7_M_58ylZTdOOMSYsE864BXmphm6EFKehp0Og43uKIWJLxzRkjD1tMcUD5HhACn1LDzFDN9sbOq_8hjQnhNxhn7-vE3rY-5gTzPoDUp7OyEmA_YSrP1ySp-urx-q2uLu_2VaXd4UXVrNCOWaD9RwNYuOda5jSRgavTWMtk4JLgKB0GYyxomTGu9Iz6by3AY2cE0uy_e1tB9jVY4odpM96gFj_GEN6red3ot9jDTKwUsJco0CFBh3H1pcYeOBWsZbLLxkUZC0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Comparison of purified protein derivative and vitamin D in the treatment of recalcitrant warts</title><source>DOAJ Directory of Open Access Journals</source><creator>Leena Raveendra ; Belliappa Pemmanda Raju ; Kumar K C Dharam ; Vinutha Mohan Kumar Yadav</creator><creatorcontrib>Leena Raveendra ; Belliappa Pemmanda Raju ; Kumar K C Dharam ; Vinutha Mohan Kumar Yadav</creatorcontrib><description>Background: Viral warts are caused by human papillomavirus. There are various treatment modalities which cause destruction of the warts. Not all of them are very effective on difficult-to-treat warts. For the treatment of difficult-to-treat warts, new and effective treatment includes intralesional immunotherapy. Objectives: The aim was to evaluate and compare the efficacy of intralesional Vitamin D and tuberculin purified protein derivative (PPD) as immunotherapy in difficult-to-treat warts. Materials and Methods: A total of 100 patients with difficult-to-treat viral warts were enrolled in this randomized controlled study. Group A patients were injected intralesionally with 2.5 TU of tuberculin PPD (0.1 ml) and Group B patients were injected with 0.1 ml of Vitamin D3 per lesion to a maximum of ten lesions. The clinical assessment was done by photographic measurements at baseline, before each treatment session, and after the completion of the treatment every 2 weeks for a total of four sessions. Unpaired t-test was used to compare both the treatment modalities. Results: In Group A, a total of 38 (76%) patients showed complete clearance and 12 (24%) showed partial response, while in Group B, a total of 42 (84%) patients showed complete clearance, while 8 (16%) showed partial response. There was no statistically significant difference between both the modalities. Conclusions: Intralesional Vitamin D3 injection and intralesional PPD may be a treatment option for difficult-to-treat warts that are unresponsive to conventional treatments. Both are equally effective with minimal side effects.</description><identifier>ISSN: 2542-551X</identifier><identifier>EISSN: 2542-5528</identifier><identifier>DOI: 10.4103/CDR.CDR_51_20</identifier><language>eng</language><publisher>Wolters Kluwer Medknow Publications</publisher><subject>recalcitrant warts ; tuberculin purified protein derivative ; vitamin d3</subject><ispartof>Clinical dermatology review, 2021-01, Vol.5 (1), p.54-58</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2850-4908f8c1e6eebc99b04563fc56b8803213aaf457f6682706c97c039cc8fe63803</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,2096,27903,27904</link.rule.ids></links><search><creatorcontrib>Leena Raveendra</creatorcontrib><creatorcontrib>Belliappa Pemmanda Raju</creatorcontrib><creatorcontrib>Kumar K C Dharam</creatorcontrib><creatorcontrib>Vinutha Mohan Kumar Yadav</creatorcontrib><title>Comparison of purified protein derivative and vitamin D in the treatment of recalcitrant warts</title><title>Clinical dermatology review</title><description>Background: Viral warts are caused by human papillomavirus. There are various treatment modalities which cause destruction of the warts. Not all of them are very effective on difficult-to-treat warts. For the treatment of difficult-to-treat warts, new and effective treatment includes intralesional immunotherapy. Objectives: The aim was to evaluate and compare the efficacy of intralesional Vitamin D and tuberculin purified protein derivative (PPD) as immunotherapy in difficult-to-treat warts. Materials and Methods: A total of 100 patients with difficult-to-treat viral warts were enrolled in this randomized controlled study. Group A patients were injected intralesionally with 2.5 TU of tuberculin PPD (0.1 ml) and Group B patients were injected with 0.1 ml of Vitamin D3 per lesion to a maximum of ten lesions. The clinical assessment was done by photographic measurements at baseline, before each treatment session, and after the completion of the treatment every 2 weeks for a total of four sessions. Unpaired t-test was used to compare both the treatment modalities. Results: In Group A, a total of 38 (76%) patients showed complete clearance and 12 (24%) showed partial response, while in Group B, a total of 42 (84%) patients showed complete clearance, while 8 (16%) showed partial response. There was no statistically significant difference between both the modalities. Conclusions: Intralesional Vitamin D3 injection and intralesional PPD may be a treatment option for difficult-to-treat warts that are unresponsive to conventional treatments. Both are equally effective with minimal side effects.</description><subject>recalcitrant warts</subject><subject>tuberculin purified protein derivative</subject><subject>vitamin d3</subject><issn>2542-551X</issn><issn>2542-5528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNo9TslKBDEQDaLgMM7Re36gx-ydHKXHZUAQRMGTTXW6ohmmF9JxxL-3XfBQ9RZePYqQc87WijN5UW0e1vPUmteCHZGF0EoUWgt7_M_58ylZTdOOMSYsE864BXmphm6EFKehp0Og43uKIWJLxzRkjD1tMcUD5HhACn1LDzFDN9sbOq_8hjQnhNxhn7-vE3rY-5gTzPoDUp7OyEmA_YSrP1ySp-urx-q2uLu_2VaXd4UXVrNCOWaD9RwNYuOda5jSRgavTWMtk4JLgKB0GYyxomTGu9Iz6by3AY2cE0uy_e1tB9jVY4odpM96gFj_GEN6red3ot9jDTKwUsJco0CFBh3H1pcYeOBWsZbLLxkUZC0</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Leena Raveendra</creator><creator>Belliappa Pemmanda Raju</creator><creator>Kumar K C Dharam</creator><creator>Vinutha Mohan Kumar Yadav</creator><general>Wolters Kluwer Medknow Publications</general><scope>DOA</scope></search><sort><creationdate>20210101</creationdate><title>Comparison of purified protein derivative and vitamin D in the treatment of recalcitrant warts</title><author>Leena Raveendra ; Belliappa Pemmanda Raju ; Kumar K C Dharam ; Vinutha Mohan Kumar Yadav</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2850-4908f8c1e6eebc99b04563fc56b8803213aaf457f6682706c97c039cc8fe63803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>recalcitrant warts</topic><topic>tuberculin purified protein derivative</topic><topic>vitamin d3</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leena Raveendra</creatorcontrib><creatorcontrib>Belliappa Pemmanda Raju</creatorcontrib><creatorcontrib>Kumar K C Dharam</creatorcontrib><creatorcontrib>Vinutha Mohan Kumar Yadav</creatorcontrib><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Clinical dermatology review</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leena Raveendra</au><au>Belliappa Pemmanda Raju</au><au>Kumar K C Dharam</au><au>Vinutha Mohan Kumar Yadav</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of purified protein derivative and vitamin D in the treatment of recalcitrant warts</atitle><jtitle>Clinical dermatology review</jtitle><date>2021-01-01</date><risdate>2021</risdate><volume>5</volume><issue>1</issue><spage>54</spage><epage>58</epage><pages>54-58</pages><issn>2542-551X</issn><eissn>2542-5528</eissn><abstract>Background: Viral warts are caused by human papillomavirus. There are various treatment modalities which cause destruction of the warts. Not all of them are very effective on difficult-to-treat warts. For the treatment of difficult-to-treat warts, new and effective treatment includes intralesional immunotherapy. Objectives: The aim was to evaluate and compare the efficacy of intralesional Vitamin D and tuberculin purified protein derivative (PPD) as immunotherapy in difficult-to-treat warts. Materials and Methods: A total of 100 patients with difficult-to-treat viral warts were enrolled in this randomized controlled study. Group A patients were injected intralesionally with 2.5 TU of tuberculin PPD (0.1 ml) and Group B patients were injected with 0.1 ml of Vitamin D3 per lesion to a maximum of ten lesions. The clinical assessment was done by photographic measurements at baseline, before each treatment session, and after the completion of the treatment every 2 weeks for a total of four sessions. Unpaired t-test was used to compare both the treatment modalities. Results: In Group A, a total of 38 (76%) patients showed complete clearance and 12 (24%) showed partial response, while in Group B, a total of 42 (84%) patients showed complete clearance, while 8 (16%) showed partial response. There was no statistically significant difference between both the modalities. Conclusions: Intralesional Vitamin D3 injection and intralesional PPD may be a treatment option for difficult-to-treat warts that are unresponsive to conventional treatments. Both are equally effective with minimal side effects.</abstract><pub>Wolters Kluwer Medknow Publications</pub><doi>10.4103/CDR.CDR_51_20</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2542-551X |
ispartof | Clinical dermatology review, 2021-01, Vol.5 (1), p.54-58 |
issn | 2542-551X 2542-5528 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_a3f073a2704a4fbe91edc7ef1f1840d1 |
source | DOAJ Directory of Open Access Journals |
subjects | recalcitrant warts tuberculin purified protein derivative vitamin d3 |
title | Comparison of purified protein derivative and vitamin D in the treatment of recalcitrant warts |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T18%3A24%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20purified%20protein%20derivative%20and%20vitamin%20D%20in%20the%20treatment%20of%20recalcitrant%20warts&rft.jtitle=Clinical%20dermatology%20review&rft.au=Leena%20Raveendra&rft.date=2021-01-01&rft.volume=5&rft.issue=1&rft.spage=54&rft.epage=58&rft.pages=54-58&rft.issn=2542-551X&rft.eissn=2542-5528&rft_id=info:doi/10.4103/CDR.CDR_51_20&rft_dat=%3Cdoaj%3Eoai_doaj_org_article_a3f073a2704a4fbe91edc7ef1f1840d1%3C/doaj%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2850-4908f8c1e6eebc99b04563fc56b8803213aaf457f6682706c97c039cc8fe63803%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |